Dyne Therapeutics has granted inducement equity awards to 12 newly hired employees under Nasdaq Listing Rule 5635(c)(4). The awards consist of non-statutory stock options to purchase up to an aggregate of 358,600 shares of common stock at an exercise price equal to the July 21, 2026 closing price, and restricted stock units covering an aggregate of 116,500 shares. The stock options have a ten-year term and vest over four years, while the restricted stock units vest in four equal annual installments, both subject to continued service.
Dyne Therapeutics IncInducement equity awards to new hires are routine and not material to company performance.